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Abstract 
A novel series of quinazoline compounds (2-14) incorporating biologically active 
heterocyclic moieties were designed and synthesized. The structure of the newly 
synthesized compounds was recognized on the basis of elemental analyses, IR, 1H-NMR, 
13C-NMR and mass spectral data. All compounds were evaluated for their ability to 
induce the cytoprotective enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1) using a 
quantitative bioassay and a docking study was performed in the Kelch domain of Keap1 
obtained from the Protein Data Bank (PDB ID: 4IQK) to explore the ability of the 
synthesized compounds to block the Nrf2-binding site of Keap1 . All of the synthesized 
compounds showed concentration-dependent inducer activity with potencies in the low- 
or sub-micromolar range. Compound 12 was the most potent inducer in this new series, 
with a concentration that doubles the specific activity of NQO1 (CD value) of 70 nM. 
The identification of this compound offers a new chemical scaffold for future 
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Introduction 
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a cytosolic enzyme that catalyses the 
obligatory two-electron reduction of many endogenous and environmental quinones 
using flavin adenine dinucleotide (FAD) as a cofactor 1-3. It is a homodimer and is 
biochemically distinguished by its prominent ability to use either NADH or NADPH as 
hydride donors, and by its inhibition by the anticoagulant dicumarol 4.  
 
NQO1 is generally considered as a detoxification enzyme due to its ability to metabolize 
reactive quinones and quinone imines to their less reactive and less toxic hydroquinone 
forms. NQO1 is a substantially inducible enzyme that is expressed in many tissues, and 
its expression is regulated by the antioxidant response element (ARE) both in basal and 
oxidative stress conditions 5. The gene encoding NQO1 contains ARE sequence in the 
promoter region and is known to be regulated by NF-E2 p45-related factor 2 (Nrf2, gene 
name Nfe2l2) 6. Nrf2 belongs to the basic leucine zipper transcription factor family, a 
member of the Cap ’n’ Collar family of transcription factors that binds to the ARE 
leading to induction of many cytoprotective and antioxidant genes. Under basal 
conditions, Nrf2 is continuously targeted for ubiquitination and proteasomal degradation, 
which is primarily mediated by Kelch-like ECH-associated protein 1 (Keap1), a Cullin-
3/Rbx1 ubiquitin ligase substrate adaptor protein 7, 8. Keap1 has specific highly reactive 
cysteine residues which serve as sensors for small molecule oxidants and electrophiles 9, 
10, resulting in inactivation of the substrate adaptor activity of Keap1, and consequently to 
Nrf2 stabilization, which then binds to the ARE (as a heterodimer with a small Maf 
transcription factor) and regulates expression and induction of its target genes, including 
NQO1 11. Indeed, Nrf2 knockout cells and animals exhibit reduction in the constitutive 
expression of NQO1 and impaired induction 5. NQO1 gene expression is induced 
together with other detoxifying enzyme genes in response to antioxidants, xenobiotics, 
electrophiles, heavy metals, and radiation 12. Upon entering cells, these inducers can 
directly scavenge free radicals and can also provoke electrophilic stress signals that 
trigger proteins linked to diverse cellular signaling pathways 6-11, 12. Evidence for the 
significance of the antioxidant functions of NQO1 in suppression of oxidative stress is 
provided by manifestations that induction of NQO1 levels or its reduction are associated 
with reduced and raised susceptibilities to oxidative stress, respectively 6-11, 12.  
 
Quinazolines are excellent reservoir of bioactive substances. A number of biological 
activities 13-17 are associated with quinazolines especially antioxidant activity 18. 
The stability of the quinazoline nucleus has inspired medicinal chemists to introduce 
many bioactive moieties to this nucleus to synthesize new potential medicinal agents.  
In the present study, and in continuation of our research programme aiming to synthesize 
biologically active heterocycles 18-20 particularly quinazoline derivatives 21, 22 several 
amino nitrogenous heterocyclic moieties have been incorporated at position -4- of the 
quinazoline to develop novel series 4- amino-substituted-quinazoline derivatives that are 
likely to have superior cytoprotective activity. In addition, a docking study was 
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performed in the Kelch domain of Keap1 obtained from the Protein Data Bank (PDB ID: 




Materials and Methods 
Melting points (uncorrected) were determined in open capillary on a Gallen Kamp 
melting point apparatus (Sanyo Gallen Kamp, Southborough, UK). Precoated silica gel 
plates (Kieselgel 0.25 mm, 60 F254, Merck, Darmstadt, Germany) were used for thin 
layer chromatography. A developing solvent system of chloroform/methanol (8:2) was 
used and the spots were detected by ultraviolet light. IR spectra (KBr disc) were recorded 
using an FT-IR spectrometer (Perkin Elmer, Norwalk, CT, USA). 1H-NMR spectra were 
scanned on a NMR spectrometer (Bruker AXS Inc., Flawil, Switzerland), operating at 
500 MHz for 1H- and 125.76 MHz for 13C. Chemical shifts are expressed in δ-values 
(ppm) relative to TMS as an internal standard, using DMSO-d6 as a solvent. Mass spectra 
were recorded on a 600 GC/MS (Clarus, Middletown, CT, USA) and TQ 320 
GC/MS/MS mass spectrometers (Varian, West Sussex, UK). Elemental analyses were 
done on a model 2400 CHNSO analyser (Perkin Elmer, Norwalk, CT, USA). All values 
were within ± 0.4 % of the theoretical values. All reagents used were of AR grade. The 
starting material 4-chloro-2-phenylquinazoline 1 was purchased from Sigma (St. Louis, 
MO, USA) and was directly used for the preparation of target compounds. 
Chemistry 
General Procedure 
Synthesis of aminoquinazoline derivatives (2-14). 
A mixture of 1 (2.41 gm, 0.01 mole) and required amines (0.01 mole) in dry 
dimethylformamide (20 mL) was heated under reflux for 24 h, then left to cool. The solid 
product formed was collected by filtration and recrystallized from dioxane to give 
compounds 2-15, respectively.  
2-Phenyl-N-(pyridine-2-yl)quinazolin-4-amine (2).  
Yield, 86%; m.p.>360oC. IR (KBr, cm-1): 3411 (NH), 3057 (CH arom.), 1618 (C=N). 1H- 
NMR (DMSO-d6): 7.5-8.3 [m, 13H, Ar-H], 12.5 [s, 1H, NH, exchangeable with D2O]. 
13C- NMR (DMSO-d6): 102.6, 117.0 (2), 126.3, 127.9 (2), 128.2, 129.0 (2), 131.6 (2), 
133.1, 135.0, 147.6 (2), 153.7, 160.7 (2).  MS m/z (%):  298 (M+) (10.43), 221 (100). 
Anal. Calcd. For C19H14N4(298.12): C, 76.49; H, 4.73; N, 18.78. Found: C, 76.18; H, 
4.45; N, 18.50. 




N-(2-chloropyridin-3-yl) -2-phenylquinazolin-4-amine (4).  
Yield, 86%; m.p. 243.2oC. IR (KBr, cm-1): 3414 (NH), 3058 (CH arom.), 1601 (C=N), 
696 (C-Cl).1H- NMR (DMSO-d6): 7.3-8.2 [m, 12H, Ar-H], 12.5 [s, 1H, NH, 
exchangeable with D2O]. 
13C- NMR (DMSO-d6): 117.2, 121.4 (2), 126.3, 127.0 (2), 
127.9, 128.2, 129.0 (2), 131.8 (2), 133.1 (2), 135.0, 152.8 (2), 162.7 (2). MS m/z (%):  
333 (M+) (17.35), 295 (100). Anal. Calcd. For C19H13ClN4 (333.08): C, 68.57; H, 3.94; N, 
16.84. Found: C, 68.26; H, 3.66; N, 17.09. 
N-(5-chloropyridin-2-yl) -2-phenylquinazolin-4-amine (5).  
Yield, 91%; m.p. 108.9oC. IR (KBr, cm-1): 3299 (NH), 3058 (CH arom.), 1623 (C=N), 
826 (C-Cl).1H- NMR (DMSO-d6): 6.5-8.5 [m, 12H, Ar-H], 12.5 [s, 1H, NH, 
exchangeable with D2O]. 
13C- NMR (DMSO-d6): 109.9, 115.3, 121.4, 125.3, 126.8 (2), 
127.0, 127.8, 128.6 (2), 131.2, 133.1, 135.0, 137.3, 145.5, 152.8, 158.8, 162.7, 163.4. MS 
m/z (%):  333 (M+) (8.48), 205 (100). Anal. Calcd. For C19H13ClN4 (333.08): C, 68.57; H, 
3.94; N, 16.84. Found: C, 68.19; H, 3.62; N, 16.49. 
2-Phenyl-N-(pyrimidin-2-yl) quinazolin-4-amine (6).  
Yield, 81%; m.p. 98.6oC. IR (KBr, cm-1): 3413 (NH), 3060 (CH arom.), 1615 (C=N). 1H- 
NMR (DMSO-d6): 7.0-8.4 [m, 12H, Ar-H], 11.1 [s, 1H, NH, exchangeable with D2O]. 
13C- NMR (DMSO-d6): 114.7 (2), 114.6, 115.8, 124.1, 125.7 (2), 126.4, 127.8, 128.7 (2), 
129.7, 131.2, 131.9, 150.6, 156.4 (2), 161.3, 161.9, 170.6. MS m/z (%):  299 (M+) 
(11.63), 204 (100). Anal. Calcd. For C18H13N5(299): C, 72.23; H, 4.38; N, 23.40. Found: 
C, 72.57; H, 4.07; N, 23.18. 
N-(4,6-dimethylpyrimidin 2-yl) -2-phenylquinazolin-4-amine (7).  
Yield, 69%; m.p. 70.1oC. IR (KBr, cm-1): 3413 (NH), 3063 (CH arom.), 2957, 2876, 
2805 (CH aliph.), 1615 (C=N). 1H- NMR (DMSO-d6): 2.5 [s, 6H, 2CH3], 7.3-8.5 [m, 
10H, Ar-H], 12.5 [s, 1H, NH, exchangeable with D2O]. 
13C- NMR (DMSO-d6): 23.9 (2), 
114.8 (2), 124.8, 126.5 (2), 128.2, 128.3, 129.5 (2), 130.5, 132.8, 138.8, 152.7, 158.3 (2), 
163.2 (3). MS m/z (%):  327.15 (M+) (3.42), 251 (100). Anal. Calcd. For 
C20H17N5(327.15): C, 73.37; H, 5.23; N, 21.39. Found: C, 73.61; H, 4.87; N, 21.07. 
1, 3-Dimethyl-6-( 2-phenylquinazolin-4-ylamino) pyrimidine- 2,4(1H,3H)dione  (8).  
Yield, 77%; m.p. 343.8oC. IR (KBr, cm-1): 3404 (NH), 3100 (CH arom.), 2928, 2836 (CH 
aliph.), 1711, 1675 (2C=O),1608 (C=N). 1H- NMR (DMSO-d6): 3.2, 33 [2s, 6H, 2N-
CH3], 7.0 [s, 1H, CH pyrimidine], 7.4- 8.4 [m, 10H, Ar-H], 9.0 [s, 1H, NH, exchangeable 
with D2O]. 
13C- NMR (DMSO-d6): 28.0, 29.9, 86.2, 114.7, 124.2, 126.5 (2), 127.0, 128.1, 
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128.6 (2), 129.0, 131.8, 132.7, 150.8, 151.3, 160.7, 163.2, 163.8, 165.5. MS m/z (%):  
359 (M+) (5.39), 219 (100). Anal. Calcd. For C20H17N5O2 (359.14): C, 66.84; H, 4.77; N, 
19.49. Found: C, 66.48; H, 4.36; N, 19.11. 
5-(2-Phenylquinazolin-4-ylamino)pyrimidine-2, 4(1H, 3H)-dione (9) 
Yield, 77%; m.p.>360oC. IR (KBr, cm-1): 3428, 3400 (NH), 3066 (CH arom.), 1699, 
1684 (2C=O),1618 (C=N). 1H- NMR (DMSO-d6): 7.4- 8.4 [m, 10H, Ar-H], 9.1 [s, 1H, 
NH, exchangeable with D2O], 11.0 [s, 1H, NHCO, exchangeable with D2O], 11.7 [s, 1H, 
CO-NH-CO, exchangeable with D2O]. 
13C- NMR (DMSO-d6): 114.1, 123.2, 126.4 (2), 
128.3 (2), 128.5 (2), 128.8 (2), 130.7, 133.6, 136.6, 150.6, 150.9, 159.6, 162.1, 162.7. MS 
m/z (%):  331 (M+) (17.32), 220 (100). Anal. Calcd. For C18H13N5O2 (331.11): C, 65.25; 
H, 3.95; N, 21.14. Found: C, 65.55; H, 4.26; N, 21.46. 
N-(5-Bromopyrimidine -2-yl)-2-phenylquinazolin-4-amine (10) 
Yield, 89%; m.p. 233.2oC. IR (KBr, cm-1): 3328 (NH), 3085 (CH arom.), 1618 (C=N). 
1H- NMR (DMSO-d6): 6.8- 8.6 [m, 11H, Ar-H], 12.5 [s, 1H, NH, exchangeable with 
D2O]. 
13C- NMR (DMSO-d6): 105.6, 114.8, 126.3, 126.5 (2), 127.0, 128.2, 128.7 (2), 
130.5, 131.8, 133.2, 152.0, 158.3 (2), 159.5, 162.5, 163.3. MS m/z (%):  378 (M+) 
(64.21), 296 (100). Anal. Calcd. For C18H12BrN5(378.23): C, 57.16; H, 3.20; N, 18.52. 
Found: C, 56.84; H, 3.54; N, 18.18. 
2-Phenyl-N-(pyrazin-2-yl) quinazolin-4-amine (11).  
Yield, 90%; m.p. 115.8oC. IR (KBr, cm-1): 3448 (NH), 3062 (CH arom.), 1612 (C=N). 
1H- NMR (DMSO-d6): 7.0-8.4 [m, 12H, Ar-H], 12.5 [s, 1H, NH, exchangeable with 
D2O]. 
13C- NMR (DMSO-d6): 114.8, 114.8, 126.3, 127.9 (2), 128.2, 128.4, 129.0 (2), 
130.5, 131.2, 132.8, 133.1, 135.0, 139.8, 149.2, 152.7, 162.7, 163.2. MS m/z (%):  299 
(M+) (8.37), 222 (100). Anal. Calcd. For C18H13N5(299.33): C, 72.23; H, 4.38; N, 23.40. 
Found: C, 72.57; H, 4.07; N, 23.18. 
6-Phenyl-8H-benzo[g]quinazolino[4,3-b]quinazolin-8-one (12).  
Yield, 69%; m.p. 157.8 oC. IR (KBr, cm-1): 3050 (CH arom.), 1675 (C=O), 1593 (C=N). 
1H-NMR (DMSO-d6): 7.2-8.8 [m, 15H, Ar-H], 
13C- NMR (DMSO-d6): 118.1, 121.2, 
125.7, 126.4, 127.0, 127.7 (2), 127.9 (2), 128.1, 128.2, 128.4 (2), 128.5, 129.7, 129.8, 
130.0, 130.8, 133.6, 134.3, 150.0, 150.6, 157.6 (2), 170.8. MS m/z (%):  373 (M+) 
(47.82), 344 (100). Anal. Calcd. For C25H15N3O (373.41): C, 80.41; H, 4.05; N, 11.25. 
Found: C, 80.76; H, 4.33; N, 10.88. 
N-(5,6-Dimethyl-1,2,4-triazin -3-yl)- 2-phenylquinazolin-4-amine (13) 
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Yield, 80%; m.p. > 360oC. IR (KBr, cm-1): 3410 (NH), 3100 (CH arom.), 2958, 2847 
(CH aliph.), 1617 (C=N). 1H- NMR (DMSO-d6): 2.4, 2.6 [2s, 6H, 2CH3], 6.7- 8.6 [m, 
9H, Ar-H], 12.5 [s, 1H, NH, exchangeable with D2O]. 
13C- NMR (DMSO-d6): 18.5, 23.0, 
114.7, 124.8, 126.5 (2), 127.0, 127.9, 128.4 (2), 130.5, 131.8, 133.1, 138.8, 147.3, 149.2, 
158.3, 162.7, 163.2. MS m/z (%):  328 (M+) (2.23), 205 (100). Anal. Calcd. For C19H16N6 
(328.14): C, 69.50; H, 4.91; N, 25.59. Found: C, 69.23; H, 4.64; N, 25.27. 
9-Ethyl-N-(2-phenylquinazolin-4-yl)-9H-carbazol-3-amine (14) 
Yield, 91%; m.p. 135.7oC. IR (KBr, cm-1): 3413 (NH), 3052 (CH arom.), 2970, 2882 (CH 
aliph.), 1618 (C=N). 1H- NMR (DMSO-d6): 1.3 [t, 3H, CH3], 4.4 [q, 2H, CH2], 7.2- 8.8 
[m, 16H, Ar-H], 10.0 [s, 1H, NH, exchangeable with D2O]. 
13C- NMR (DMSO-d6): 14.2, 
37.5, 109.2 (3), 109.7 (2), 114.5, 115.1, 119.2, 120.4, 122.3, 123.5, 126.2, 128.3 (2), 
128.7 (2), 130.7, 131.4 (2), 133.5 (2), 137.1, 138.9, 150.6, 158.6, 159.6. MS m/z (%):  
415 (M+) (19.53), 372 (100). Anal. Calcd. For C28H22N4(414.50): C, 81.13; H, 5.35; N, 
13.52. Found: C, 81.44; H, 5.04; N, 13.26. 
 
Evaluation of biological activity 
The compounds were evaluated for their ability to induce NQO1 using a quantitative 
microtiter plate assay in Hepa1c1c7 murine hepatoma cells as described previously 24. 
The results are expressed as the ratio of the specific enzyme activity in cell lysates 
prepared from treated over control wells. The CD value (Concentration of a compound 
required to Double the specific enzyme activity) represents a measure of inducer potency. 
Each compound was tested at 8 different concentrations in 8 replicate wells. Each 
experiment was performed three times.   
Molecular modeling study  
The structures of the synthesized 2-phenylquinazoline-4-amine derivatives were built 
according to the default parameters, using the MOE software version 10.2009. Geometry 
optimization as well as a systematic conformational search was carried out to an RMS 
gradient of 0.01 Å employing the ConfSearch module implemented in MOE. All 
computations were performed with the Merck Force Field (MMFF94s). Molecular 
docking study was performed using the crystallographic structure of the Kelch domain of 
Keap1 obtained from the Protein Data Bank (PDB ID: 4IQK) to explore the ability of the 
synthesized compounds to block the Nrf2-binding site of Keap1. The protein target was 
prepared for docking by addition of the missing hydrogens and calculating the partial 
charges. Internal validation was performed to the native ligand followed by docking of 
the compounds where the target protein was kept rigid, while ligands were allowed to 
rotate to accommodate freely inside the protein cavity. Following multiple separate 
docking simulations using default parameters, the best conformations were chosen based 
on the combination of S score data, E conformation and appropriate fitting with the 





Results and Discussion 
Chemistry 
4-Chloro-2-phenylquinazoline was used as a key starting material for the synthesis of the 
target compounds. Synthesis of quinazoline derivatives 2-14 has been achieved by 
substituting 4-chloro group in the starting 1 with different amino nitrogenous heterocyclic 
moieties namely, 2-amino pyridine, 4-amino pyridine, 3-amino-2-chloro pyridine, 2-
amino-5-chloro pyridine, 2-amino pyrimidine, 2-amino-4,6-dimethyl pyrimidine, 6-
amino-1,3-dimethyl uracil, 5-amino uracil, 2-amino-5-bromopyrimidine, 2-amino 
pyrazine, 3-amino-2-naphthoic acid, 3-amino-5,6-dimethyl-1,2,4-triazine and 3-amino-9-
ethyl carbazole as outlined in scheme 1. In this work, ten novel compounds, a reported 
compound 3 23 and two commercially available compounds 4 and 6 were synthesized in 
order to explore their cytoprotective activity. 
The synthesized quinazoline derivatives were characterized by IR, 1H-NMR,13C-NMR 
and mass spectra. The IR spectra of the compounds perfectly exhibited the absorption 
bands for NH, CH aromatic and C=N around 3328-3448, 3042-3100, 1601-1625 cm-1, 
respectively. 
In the 1H-NMR spectrum, aromatic protons were observed as complex mulitiplets in the 
range of δ 6.5-8.8 ppm. In addition, there is one exchangeable secondary amide (-NH) 
proton in the structures and are observed as broad singlet around δ 9.0-12.5 ppm to prove 
the introduction of the amino substitution to the structures. 
13C-NMR spectra exhibited additional signals for the introduced heterocyclic moieties in 
the aromatic region around δ 119.2-170.6 ppm which is in conformity with the assigned 
structures. 
The mass spectra of the compounds showed molecular ion peaks at their respective m/e 
along with the elemental analyses which were found within the limit of 0.4% of 
theoretical values for all the synthesized compounds. 
 
Biological evaluation 
All of the new compounds showed a concentration-dependent inducer activity (Figure 1). 
The inducer potencies ranged between 5.5 M (compound 4) and 70 nM (compound 12) 
(Table 1). Thus, compound 12 is approximately 80 times more potent than compound 4. 
Notably, in this series, compound 12 uniquely contains a structurally rigid substituent, 
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strongly suggesting that in addition to chemical reactivity, structural rigidity which 
perhaps affects its ability to bind to the inducer sensor Keap1, is an important 
determinant of inducer potency. 
Molecular modeling study  
Keap1 binds to Nrf2 promoting its degradation, resulting in low levels of cytoprotective 
gene products. Various compounds were reported to bind to the Keap1 Kelch domain and 
antagonize its activity 6-11, 12. For assessing the ability of the newly synthesized 
compounds to access and block the Kelch domain of Keap1, a molecular docking study 
was performed using the Keap1 crystal coordinates obtained from the Protein Data Bank 
(PDB ID: 4IQK). The main interactions observed between the validated native ligand and 
the protein target were found to be arene-cation interaction with Arg415, arene-arene 
interaction with Tyr525 and 3 hydrogen bonds with Ser602, Ser508 and Ser555 with S = 
-13.306 Kcal/mol and rmsd 0.6635 Kcal/mol/Å (Figure 2). Upon docking of the 
synthesized compounds, they all showed an arene–cation binding interaction with 
Arg415 via their aromatic rings and one of the nitrogen atoms of quinazoline ring. 
Whereas, Compound 12 (S= -9.571 Kcal/mol) has adopted a conformation allowing the 
presence of additional arene-arene interaction with Tyr525 and arene–cation interactions 
with Arg483 (Figure 3).    
Conclusion 
This work was aimed to synthesize novel 4-amino-substituted-quinazoline derivatives as 
NAD(P)H: quinone oxidoreductase 1 inducers (NQO1). NQO1 is a versatile 
cytoprotective enzyme which has prominent antioxidant functions due to of its ability to 
metabolize reactive endogenous and exogenous (dietary or environmental) quinones to 
their less reactive and less toxic hydroquinone forms by obligatory 2-electron reduction, 
thereby diverting them from redox cycling reactions and depletion of intracellular 
antioxidants, such as glutathione. Thus, NQO1 inducers could be of potential therapeutic 
benefit in oxidative stress-mediated pathologies, such as neurodegenerative diseases. The 
new compounds showed a concentration-dependent inducer activity with potencies in the 
low- to sub-micromolar range. Compound 12, which uniquely contains a structurally 
rigid substituent, is the most potent inducer in this series with activity in the nanomolar 
concentration range. Molecular docking of the synthesized compounds as Keap1-Nrf2 
protein-protein interaction inhibitors was performed. Compound 12 was found to bind to 
key amino acids in the binding site. These compounds represent promising quinazoline 
scaffold-based leads for further optimization as cytoprotective agents.  
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